Find Clinical Trials & Studies

Visit the Research & Education Institute

Oral Cyclin A/B-RxL Inhibitor CID-078 in Advanced Solid Tumor Malignancies

I'm Interested!

Please call
1-800-641-2422

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor

Study Purpose

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.

Principal Investigator
Afshin Dowlati MD

Department/Division
Cancer (Any Solid Tumor)

UH IRB: STUDY20240790
StudyID: CPI1Y24
ClinicalTrials.gov: NCT06577987

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422